Search

Search Constraints

You searched for: Author/Creator Conesa, Arantxa

Search Results

1. AB0577 TOCILIZUMAB IN GIANT CELL ARTERITIS. ROUTE OF ADMINISTRACION: INTRAVENOUS OR SUBCUTANEOUS. (June 2019)

2. AB0749 ARE THERE ANY DIFFERENCES IN THE EFFECTIVITY AND SAFETY OF CERTOLIZUMAB PEGOL IN PATIENTS WITH PSORIATIC ARTHRITIS ACCORDING THEIR GENDER?. (June 2019)

3. AB1077 ANTI-IL6-RECEPTOR TOCILIZUMAB IN GRAVES' ORBITOPATHY. MULTICENTER STUDY OF 46 PATIENTS IN CLINICAL PRACTICE. (June 2019)

5. FRI0276 TIME OF DISEASE EVOLUTION AND EFFICACY OF TOCILIZUMAB IN GIANT CELL ARTERITIS. (June 2019)

6. FRI0277 ISCHEMIC AND SYSTEMIC SYMPTOMS IN GIANT CELL ARTERITIS PATIENTS, RESPONSE TO TOCILIZUMAB. (June 2019)

7. FRI0427 IS THE CLINICAL AND THERAPEUTIC PROFILE RELATED TO SATISFACTORY RESPONSE TO APREMILAST IN PSORIATIC ARTHRITIS?. (June 2019)

8. Long-term follow-up of certolizumab pegol in uveitis due to immune-mediated inflammatory diseases: multicentre study of 80 patients. Issue 2 (6th December 2022)

9. OP0339 TOCILIZUMAB IN GIANT CELL ARTERITIS. MONOTHERAPY VERSUS COMBINED WITH CONVENTIONAL IMMUNOSUPPRESSIVE DRUGS. (June 2019)

10. SAT0219 EFFICACY AND SAFETY OF TOCILIZUMAB IN GIANT CELL ARTERITIS INDEPENDENTLY OF THE INICIAL PREDNISONE DOSE. (June 2019)